1809784-29-9
1809784-29-9 structure
- Name: DTP3
- Chemical Name: DTP-3
- CAS Number: 1809784-29-9
- Molecular Formula: C26H35N7O5
- Molecular Weight: 525.600
- Catalog: Signaling Pathways Cell Cycle/DNA Damage DNA/RNA Synthesis
- Create Date: 2019-06-16 11:02:40
- Modify Date: 2024-01-21 01:32:06
-
DTP3 TFA is a potent and selective GADD45β/MKK7 inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway[1].
| Name | DTP-3 |
|---|---|
| Synonyms |
7UXW0T8LS8
D-Phenylalaninamide, N-acetyl-D-tyrosyl-D-arginyl- DTP-3 N-Acetyl-D-tyrosyl-D-arginyl-D-phenylalaninamide |
| Description | DTP3 TFA is a potent and selective GADD45β/MKK7 inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway[1]. |
|---|---|
| Related Catalog | |
| In Vitro | DTP3 (10 μM; 1-21 days) causes the potent and tumor-selective induction of JNK activation and apoptosis, as shown by the appearance of phosphorylated JNK, as early as 24 hours[2]. |
| In Vivo | DTP3 TFA (s.c.; 14.5 mg/kg/day; 28 days) has shown a dramatic shrinkage of the tumors, and virtually eradicates established subcutaneous myeloma xenografts in mice[2]. DTP3 TFA (intravenous injection; 10 mg/kg/day) has t1/2 of 1.26 hours, CL of 27.13 ML/min/kg, and Vd of 2.80 L/kg[2]. Animal Model: 6 to 8-week old male NOD/SCID mice (NOD.CB17-Prkdcscid/IcrCrl; Charles River)[2] Dosage: 14.5 mg/kg Administration: S.c.; daily; 28 days Result: Had shown a dramatic shrinkage of the tumors. Animal Model: CD1 male mice of 25-30 g[2] Dosage: 10 mg/kg (Pharmacokinetic Study) Administration: Intravenous injection Result: Had t1/2 of 1.26 hours, CL of 27.13 ML/min/kg, and Vd of 2.80 L/kg. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C26H35N7O5 |
| Molecular Weight | 525.600 |
| Exact Mass | 525.269958 |
| LogP | -0.43 |
| Appearance | powder |
| Index of Refraction | 1.637 |
| Storage condition | Store at -20°C |
| Water Solubility | 100 mg/mL (190.26 mM) |